Amylyx CLO sells shares to cover tax withholding

Amylyx Pharmaceuticals Chief Legal Officer reports automatic share sale for taxes.

Rhea-AI Filing Summary

Amylyx Pharmaceuticals Chief Legal Officer reports automatic share sale for taxes. Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, sold 3,448 shares of common stock on February 2, 2026 at a weighted average price of $14.6507 per share.

The footnotes state these shares were sold automatically to cover tax withholding obligations from vesting restricted stock units and were not at her discretion. After this transaction, she directly holds 144,693 Amylyx common shares.

Insider Trade Summary

Net Seller: 3,448 shares

Net Sell 1 txn

Insider Mazzariello Gina

Role Chief Legal Officer

Sold 3,448 shs ($51K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,448	$14.6507	$51K

Holdings After Transaction: Common Stock — 144,693 shares (Direct)

Footnotes (2)

1. F1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.470 to $14.810. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amylyx (AMLX) Chief Legal Officer report in this Form 4?

The filing shows Amylyx Chief Legal Officer Gina Mazzariello sold 3,448 common shares. The sale occurred to satisfy tax withholding tied to restricted stock unit vesting, and was executed automatically rather than at her personal trading discretion.

How many Amylyx (AMLX) shares does the insider hold after the reported sale?

Following the reported transaction, Gina Mazzariello directly owns 144,693 Amylyx common shares. This figure reflects her holdings after selling 3,448 shares to cover tax withholding obligations related to the vesting of restricted stock units on February 2, 2026.

Was the Amylyx (AMLX) insider share sale discretionary?

No. The filing explains the 3,448 shares were sold automatically to cover tax withholding obligations from restricted stock unit vesting. The footnote clarifies these sales were required for taxes and not carried out at the reporting person’s trading discretion.

What price did the Amylyx (AMLX) shares sell for in the Form 4 transaction?

The reported weighted average sale price was $14.6507 per share. Shares were sold in multiple trades within a price range from $14.470 to $14.810, and full trade-by-trade details are available to SEC staff on request, according to the filing footnote.

Who is the reporting person in this Amylyx (AMLX) insider transaction?

The reporting person is Gina Mazzariello, Amylyx Pharmaceuticals’ Chief Legal Officer. She is identified as an officer of the company, not a director or 10% owner, and the transaction involves her directly held common stock, according to the ownership designation in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:05 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazzariello Gina

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		3,448(1)	D	$14.6507(2)	144,693	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.470 to $14.810. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

	/s/ Joshua B. Cohen, as Attorney in Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.